VBI Vaccines Profit Margin

VBI Vaccines (VBIV) currently reports a profit margin of -881.79% as of March 2024. That compares with -8984.8% in the prior-year period — up 90.2% year over year. That is below the Healthcare sector average of 14.41%. Use the charts on this page to explore VBI Vaccines's profit margin history and peer comparisons.

VBI Vaccines's profit margin increased from -8984.8% to -881.79% — a 90.2% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

VBI Vaccines's profit margin of -881.79% is lower than the Healthcare sector average of 14.41%. That is roughly 6217.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but VBI Vaccines's current -881.79% should be judged against Healthcare norms (sector average: 14.41%) and against VBIV's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -881.79%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.41%. From there, open related valuation or income-statement pages for VBI Vaccines, and consider following VBIV for alerts when major investors trade the stock.